Evidence map›Paper›PMID 35254166›Full record

Observational studyMicrobiology spectrum2022

Comparative 6-Month Wild-Type and Delta-Variant Antibody Levels and Surrogate Neutralization for Adults Vaccinated with BNT162b2 versus mRNA-1273.

Brian Grunau, Liam Golding, Martin A Prusinkiewicz, Michael Asamoah-Boaheng, Richard Armour, Ana Citlali Marquez, Agatha N Jassem, Vilte Barakauskas, Sheila F O'Brien, Steven J Drews and 3 more

Open access · goldAbstract readObservational Study
In one paragraph

Observational study in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 5 institutions in 1 country.

Brian GrunauCentre for Health Evaluation & Outcome Sciences, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.ORCID 0000-0003-4103-1383
Liam GoldingDepartment of Obstetrics and Gynecology, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.
Martin A PrusinkiewiczDepartment of Pediatrics, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.
Michael Asamoah-BoahengDepartment of Emergency Medicine, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.ORCID 0000-0002-9632-6878
Richard ArmourBritish Columbia Emergency Health Services, Vancouver, British Columbia, Canada.
Ana Citlali MarquezDepartment of Pathology and Laboratory Medicine, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.
Agatha N JassemDepartment of Pathology and Laboratory Medicine, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.
Vilte BarakauskasDepartment of Pathology and Laboratory Medicine, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.
Sheila F O'BrienCanadian Blood Servicesgrid.423370.1, Ottawa, Ontario, Canada.ORCID 0000-0002-5332-2789
Steven J DrewsCanadian Blood Servicesgrid.423370.1, Ottawa, Ontario, Canada.ORCID 0000-0003-2519-1109
Scott HaigBritish Columbia Emergency Health Services, Vancouver, British Columbia, Canada.
Pascal M LavoieDepartment of Pediatrics, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.
David M GoldfarbDepartment of Pathology and Laboratory Medicine, University of British Columbiagrid.17091.3e, Vancouver, British Columbia, Canada.ORCID 0000-0003-0835-9504
University of British Columbia · CAIsland Health · CACanadian Blood Services · CAMemorial University of Newfoundland · CAUniversity of Alberta · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

While mRNA vaccines are highly efficacious against short-term COVID-19, long-term immunogenicity is less clear. We compared humoral immunogenicity between BNT162b2 and mRNA-1273 vaccines 6 months after the first vaccine dose, examining the wild-type strain and multiple Delta-variant lineages. Using samples from a prospective observational cohort study of adult paramedics, we included COVID-19-negative participants who received two BNT162b2 or mRNA-1273 vaccines, and provided a blood sample 170 to 190 days post first vaccine dose. We compared wild-type spike IgG concentrations using the Mann-Whitney U test. We also compared secondary outcomes of: receptor binding domain (RBD) wild-type antibody concentrations, and inhibition of angiotensin-converting enzyme 2 (ACE-2) binding to spike proteins from the wild-type strain and five Delta-variant lineages. We included 571 adults: 475 BNT162b2 (83%) and 96 mRNA-1273 (17%) vaccinees, with a mean age of 39 (SD = 10) and 43 (SD = 10) years, respectively. Spike IgG antibody concentrations were significantly higher (

Indexed as

COVID-19SARS-CoV-22019-nCoV Vaccine mRNA-1273AdultAntibodies, ViralBNT162 VaccineCOVID-19 VaccinesHumansmRNA VaccinesProspective Studies2019-nCoV Vaccine mRNA-1273Antibodies, ViralBNT162 VaccineCOVID-19 VaccinesmRNA VaccinesCOVID-19DeltaSARS-CoV-2spike

Identifiers

PMID35254166
PMCPMC9045183
OpenAlexW4220814478

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.